| 1 | The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 | The Lancet Gastroenterology and Hepatology | 2020 | 1,854 |
| 2 | Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study | The Lancet Gastroenterology and Hepatology | 2017 | 1,776 |
| 3 | The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis | The Lancet Gastroenterology and Hepatology | 2022 | 1,689 |
| 4 | Liver injury in COVID-19: management and challenges | The Lancet Gastroenterology and Hepatology | 2020 | 1,596 |
| 5 | Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study | The Lancet Gastroenterology and Hepatology | 2018 | 1,479 |
| 6 | Prolonged presence of SARS-CoV-2 viral RNA in faecal samples | The Lancet Gastroenterology and Hepatology | 2020 | 1,439 |
| 7 | The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 | The Lancet Gastroenterology and Hepatology | 2020 | 1,308 |
| 8 | Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis | The Lancet Gastroenterology and Hepatology | 2020 | 891 |
| 9 | Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999–2019: a systematic review and meta-analysis | The Lancet Gastroenterology and Hepatology | 2019 | 882 |
| 10 | Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis | The Lancet Gastroenterology and Hepatology | 2020 | 733 |
| 11 | Enteric involvement of coronaviruses: is faecal–oral transmission of SARS-CoV-2 possible? | The Lancet Gastroenterology and Hepatology | 2020 | 698 |
| 12 | FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study | The Lancet Gastroenterology and Hepatology | 2020 | 671 |
| 13 | Global incidence and mortality of pancreatic diseases: a systematic review, meta-analysis, and meta-regression of population-based cohort studies | The Lancet Gastroenterology and Hepatology | 2016 | 644 |
| 14 | Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis | The Lancet Gastroenterology and Hepatology | 2020 | 639 |
| 15 | The rising tide of early-onset colorectal cancer: a comprehensive review of epidemiology, clinical features, biology, risk factors, prevention, and early detection | The Lancet Gastroenterology and Hepatology | 2022 | 601 |
| 16 | Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study | The Lancet Gastroenterology and Hepatology | 2019 | 593 |
| 17 | Global, regional, and national burden of hepatitis B, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 | The Lancet Gastroenterology and Hepatology | 2022 | 569 |
| 18 | Prevalence of symptoms of anxiety and depression in patients with inflammatory bowel disease: a systematic review and meta-analysis | The Lancet Gastroenterology and Hepatology | 2021 | 564 |
| 19 | The global, regional, and national burden of pancreatic cancer and its attributable risk factors in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 | The Lancet Gastroenterology and Hepatology | 2019 | 534 |
| 20 | The global, regional, and national burden of stomach cancer in 195 countries, 1990–2017: a systematic analysis for the Global Burden of Disease study 2017 | The Lancet Gastroenterology and Hepatology | 2020 | 530 |
| 21 | The microbiota–gut–brain axis in obesity | The Lancet Gastroenterology and Hepatology | 2017 | 528 |
| 22 | A watch-and-wait approach for locally advanced rectal cancer after a clinical complete response following neoadjuvant chemoradiation: a systematic review and meta-analysis | The Lancet Gastroenterology and Hepatology | 2017 | 523 |
| 23 | Laparoscopic versus open pancreatoduodenectomy for pancreatic or periampullary tumours (LEOPARD-2): a multicentre, patient-blinded, randomised controlled phase 2/3 trial | The Lancet Gastroenterology and Hepatology | 2019 | 514 |
| 24 | Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study | The Lancet Gastroenterology and Hepatology | 2022 | 499 |
| 25 | Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial | The Lancet Gastroenterology and Hepatology | 2021 | 493 |
| 26 | Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis | The Lancet Gastroenterology and Hepatology | 2023 | 493 |
| 27 | Pathophysiology of irritable bowel syndrome | The Lancet Gastroenterology and Hepatology | 2016 | 491 |
| 28 | Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis | The Lancet Gastroenterology and Hepatology | 2021 | 480 |
| 29 | Global, regional, and national burden of colorectal cancer and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 | The Lancet Gastroenterology and Hepatology | 2022 | 473 |
| 30 | Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission | The Lancet Gastroenterology and Hepatology | 2019 | 472 |
| 31 | Liver diseases in the Asia-Pacific region: a Lancet Gastroenterology & Hepatology Commission | The Lancet Gastroenterology and Hepatology | 2020 | 470 |
| 32 | A global scientific strategy to cure hepatitis B | The Lancet Gastroenterology and Hepatology | 2019 | 458 |
| 33 | Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial | The Lancet Gastroenterology and Hepatology | 2016 | 453 |
| 34 | Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial | The Lancet Gastroenterology and Hepatology | 2017 | 447 |
| 35 | Type 3c (pancreatogenic) diabetes mellitus secondary to chronic pancreatitis and pancreatic cancer | The Lancet Gastroenterology and Hepatology | 2016 | 446 |
| 36 | SARS-CoV-2 in wastewater: potential health risk, but also data source | The Lancet Gastroenterology and Hepatology | 2020 | 446 |
| 37 | Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach | The Lancet Gastroenterology and Hepatology | 2021 | 438 |
| 38 | Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial | The Lancet Gastroenterology and Hepatology | 2016 | 416 |
| 39 | Early detection of pancreatic cancer | The Lancet Gastroenterology and Hepatology | 2020 | 398 |
| 40 | COVID-19 and the liver: little cause for concern | The Lancet Gastroenterology and Hepatology | 2020 | 396 |
| 41 | Faecal microbiota transplantation versus placebo for moderate-to-severe irritable bowel syndrome: a double-blind, randomised, placebo-controlled, parallel-group, single-centre trial | The Lancet Gastroenterology and Hepatology | 2018 | 387 |
| 42 | Changes in colorectal cancer incidence in seven high-income countries: a population-based study | The Lancet Gastroenterology and Hepatology | 2019 | 387 |
| 43 | The global, regional, and national burden of oesophageal cancer and its attributable risk factors in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 | The Lancet Gastroenterology and Hepatology | 2020 | 375 |
| 44 | Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial | The Lancet Gastroenterology and Hepatology | 2023 | 367 |
| 45 | Effect of a deep-learning computer-aided detection system on adenoma detection during colonoscopy (CADe-DB trial): a double-blind randomised study | The Lancet Gastroenterology and Hepatology | 2020 | 364 |
| 46 | Country, regional, and global estimates for lactose malabsorption in adults: a systematic review and meta-analysis | The Lancet Gastroenterology and Hepatology | 2017 | 362 |
| 47 | Robotic versus laparoscopic surgery for middle and low rectal cancer (REAL): short-term outcomes of a multicentre randomised controlled trial | The Lancet Gastroenterology and Hepatology | 2022 | 361 |
| 48 | The global, regional, and national burden of colorectal cancer and its attributable risk factors in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 | The Lancet Gastroenterology and Hepatology | 2019 | 345 |
| 49 | Detection of colorectal adenomas with a real-time computer-aided system (ENDOANGEL): a randomised controlled study | The Lancet Gastroenterology and Hepatology | 2020 | 344 |
| 50 | Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study | The Lancet Gastroenterology and Hepatology | 2021 | 343 |
